CWC
BPMC

Carolinas Wealth Consulting’s Blueprint Medicines BPMC Stock Holding History

Carolinas Wealth Consulting’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20
Closed -$2K – 882
2020
Q3 		$2K Buy
+20
New +$1.54K ﹤0.01% 682

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Carolinas Wealth Consulting's BPMC Position: Q4 2020 in Review

Carolinas Wealth Consulting sold out of Blueprint Medicines (BPMC) in Q4 2020, closing a stake of 20 shares — an estimated $2K sold.

Carolinas Wealth Consulting first reported a position in BPMC in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 278 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

  • Carolinas Wealth Consulting reported no remaining Blueprint Medicines position as of Q4 2020 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 20 Blueprint Medicines shares in Q4 2020, an estimated $2K.
  • Carolinas Wealth Consulting first reported a position in Blueprint Medicines in Q3 2020 and held it in 1 quarter.
  • Carolinas Wealth Consulting's Blueprint Medicines position peaked at $2K in Q3 2020.
  • 278 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2020, filed 16 Feb 2021.